Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $66

Benzinga Newsdesk www.benzinga.com Positive 90.3%

Neg 0% Neu 0% Pos 90.3%

Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and raises the price target from $62 to $66.